Drug therapy management of the febrile neutropenic cancer patient.
Neutropenia is one of the major dose-limiting toxicities of cancer chemotherapy. Since the 1960s, dramatic changes have occurred in its epidemiology, microbiology, and treatment. This article highlights these important changes; reviews the history and current practice of antibiotic, antifungal, and antiviral therapy; and looks toward future therapy using colony-stimulating factors (CSFs) for the infectious complications in the febrile neutropenic cancer patient.
Finkbiner
K L
KL
Ernst
T F
TF
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D005334:Fever / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007239:Infections / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D009369:Neoplasms / Q000150:complications*; D009503:Neutropenia / Q000188:drug therapy* / Q000209:etiology
D000890:Anti-Infective Agents; D003115:Colony-Stimulating Factors